ArticleCureus2025
Real-World Outcomes of Biologic Therapy for Severe Asthma in a High-Burden Urban Population.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Racial and Socioeconomic Differences in Real-World Use of Biologic Therapy for Asthma.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Asthma prevalence and mortality are disproportionately higher in underserved areas such as the Bronx compared to other regions of New York City. Biologic therapy is recommended for severe asthma but may present challenges in access and adherence among patients in low-resource settings. This study evaluates the real-world effectiveness and feasibility of biologic therapy in an inner-city cohort. Methods We conducted a retrospective cohort study of adult patients with severe asthma treated at an urban outpatient pulmonary and allergy clinic. Patients who received biologic therapy for at least six months between January 2020 and August 2023 were included. Outcome measures included Asthma Control Test (ACT) scores, asthma exacerbation rates, oral corticosteroid (OCS) use, lung function (forced expiratory volume in one second (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.